Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial

Journal of Immunotherapy

Volumn 37, Issue 1, 2014, Pages 26-35

  Correale, Pierpaolo ^a   Botta, Cirino ^a   Rotundo, Maria S ^a   Guglielmo, Annamaria ^d   Conca, Raffaele ^b   Licchetta, Antonella ^b   Pastina, Pierpaolo ^a   Bestoso, Elena ^a   Ciliberto, Domenico ^a   Cusi, Maria G ^a   Fioravanti, Antonella ^c   Guidelli, Giacomo M ^c   Bianco, Maria T ^a   Misso, Gabriella ^f   Martino, Elodia ^a   Caraglia, Michele ^f,g   Tassone, Pierfrancesco ^a,e   Mini, Enrico ^g   Mantovani, Giovanni ^h   Ridolfi, Ruggero ⁱ   Pirtoli, Luigi ^a   Tagliaferri, Pierosandro ^a   more..

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b Department of Pediatrics Obstetrics and Reproductive Medicine   (Italy)

^c Istituto Toscano Tumori   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e Tommaso Campanella Foundation   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h UNIVERSITY OF CAGLIARI   (Italy)

ⁱ Centro Oncologico Romagnolo   (Italy)

Author keywords

Aldesleukin; Chemoimmunotherapy; Colorectal carcinoma; Granulocyte macrophage colonystimulating factor; Phase iii trial

Indexed keywords

ACUTE PHASE PROTEIN; AUTOANTIBODY; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 2 RECEPTOR ALPHA; LACTATE DEHYDROGENASE; LEVOLEUCOVORIN; OXALIPLATIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RO ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; COLORECTAL LIVER METASTASIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; EOSINOPHIL COUNT; FEMALE; FEVER; FLUORESCENCE ACTIVATED CELL SORTING; FLUSHING; FOLLOW UP; HAZARD RATIO; HUMAN; IMMUNOBIOLOGY; IMMUNOMODULATION; IMMUNOPHENOTYPING; INNATE IMMUNITY; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MONOCYTE; MULTICENTER STUDY; NATURAL KILLER CELL; NAUSEA; NEUROTOXICITY; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SJOEGREN SYNDROME; SUDDEN DEATH; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THROMBOPHLEBITIS; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; LEUCOVORIN; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84890897595     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000004     Document Type: Article

References (33)

1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000. Cancer Incidence, Mortality and Prevalence Worldwide, IARC Cancer Base No. 5, version 1.0. Lyon, France: IARC Press; 2001.
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352: 476-487.
3. Eng C. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist. 2010;15: 73-84.
4. Yarom N, Jonker DJ. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med. 2011;11: 95-105.
5. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359: 1757-1765.
6. Proietti E, Moschella F, Capone I, et al. Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Mol Oncol. 2012;6: 1-14.
7. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118: 1991-2001. (Pubitemid 351872317)
8. Camus M, Tosolini M, Mlecnik B, et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009;69: 2685-2693.
9. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25: 2586-2593. (Pubitemid 47041232)
10. Nagorsen D, Voigt S, Berg E, et al. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med. 2007;5:62.
11. Pagès F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27: 5944-5951.
12. Bouwhuis MG, Ten Hagen TL, Eggermont AM. Immunologic functions as prognostic indicators in melanoma. Mol Oncol. 2011;5: 183-189.
13. Correale P, Cusi MG, Del Vecchio MT, et al. Dendritic cellmediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol. 2005; 175: 820-828. (Pubitemid 41094964)
14. Caraglia M, Marra M, Budillon A, et al. Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation. Cancer Biol Ther. 2005;4: 1159-1167. (Pubitemid 41598574)
15. Correale P, Messinese S, Caraglia M, et al. A novel biweekly multi-drug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pre-treated patients with advanced colorectal carcinoma. Br J Cancer. 2004;90: 1710-1714. (Pubitemid 38725639)
16. Correale P, Botta C, Cusi MG, et al. Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer. 2012;130: 1577-1589.
17. Correale P, Marra M, Remondo C, et al. Cytotoxic drugs upregulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFRtargeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer. 2010;46: 1703-1711.
18. Correale P, Cusi MG, Tsang KY, et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 2005;23: 8950-8958. (Pubitemid 46211480)
19. Correale P, Tagliaferri P, Fioravanti A, et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine+FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res. 2008;14: 4192-4199.
20. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18: 2938-2947. (Pubitemid 30644117)
21. Correale P, Rotundo MS, Botta C, et al. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res. 2012;18: 850-857.
22. Tenti S, Correale P, Conca R, et al. Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen. J Chemother. 2012;24: 245-246.
23. Correale P, Rotundo MS, Del Vecchio MT, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 2010;33: 435-441.
24. Correale P, Rotundo MS, Botta C, et al. Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. Oncoimmunology. 2012;1: 531-532.
25. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8: 59-73.
26. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagydependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334: 1573-1577.
27. Correale P, Del Vecchio MT, La Placa M, et al. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother. 2008;31: 132-147.
28. Botta C, Bestoso E, Apollinari S, et al. Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J Immunother. 2012;35: 440-447.
29. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+ CD25+regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004; 34: 336-344. (Pubitemid 39255944)
30. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105: 2862-2868. (Pubitemid 40446280)
31. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22: 633-640. (Pubitemid 33043908)
32. Botta C, Barbieri V, Ciliberto D, et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther. 2013; 14: 469-475.
33. Rossi M, Botta C, Correale P, et al. Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opin Biol Ther. 2013;13(suppl 1):S83-S93.